Literature DB >> 26594017

Blood transmission studies of prion infectivity in the squirrel monkey (Saimiri sciureus): the Baxter study.

Diane L Ritchie1, Susan V Gibson2, Christian R Abee3, Thomas R Kreil4, James W Ironside1, Paul Brown5.   

Abstract

BACKGROUND: Four secondary transmissions of variant Creutzfeldt-Jakob disease (vCJD) infectivity have been associated with the transfusion of nonleukoreduced red blood cells collected from vCJD patients during the asymptomatic phase of the disease. Establishing efficient experimental models for assessing the risk of future transmissions of vCJD infectivity via blood transfusion is of paramount importance in view of a study of archived appendix samples in which the prevalence of asymptomatic vCJD infection in the United Kingdom was estimated at approximately 1 in 2000 of the population. In this study, we investigated transmission of vCJD and sporadic CJD (sCJD) infectivity from blood using the squirrel monkey, which is highly susceptible to experimental challenge with human prion disease. STUDY DESIGN AND METHODS: Whole blood collected from vCJD- and sCJD-infected squirrel monkeys was transfused at multiple time points into recipient squirrel monkeys. Blood recipients were euthanized approximately 7 years after their first blood transfusion.
RESULTS: No clinical or pathologic signs of a prion disease were observed in either the sCJD- or the vCJD-transfused monkeys, and immunohistochemistry and biochemical investigations showed no PrP(TSE) in central nervous system or lymphoreticular tissues. Similarly, monkeys inoculated intracerebrally (IC) and intravenously (IV) with either buffy coat or plasma from vCJD and sCJD patients failed to develop disease. However, white blood cells from a chimpanzee-passaged strain of human Gerstmann-Sträussler-Scheinker (GSS) disease transmitted autopsy-proven disease to two IC-inoculated monkeys after incubation periods of 34 and 39 months.
CONCLUSION: Blood transmits GSS but not sCJD or vCJD infectivity to IC- or IV-inoculated squirrel monkeys within a 7-year observation period.
© 2015 AABB.

Entities:  

Mesh:

Year:  2015        PMID: 26594017     DOI: 10.1111/trf.13422

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

1.  Interventions to reduce the risk of surgically transmitted Creutzfeldt-Jakob disease: a cost-effective modelling review.

Authors:  Matt Stevenson; Lesley Uttley; Jeremy E Oakley; Christopher Carroll; Stephen E Chick; Ruth Wong
Journal:  Health Technol Assess       Date:  2020-02       Impact factor: 4.014

Review 2.  Non-human primates in prion diseases.

Authors:  Emmanuel E Comoy; Jacqueline Mikol; Jean-Philippe Deslys
Journal:  Cell Tissue Res       Date:  2022-06-04       Impact factor: 5.249

3.  Unexpected prion phenotypes in experimentally transfused animals: predictive models for humans?

Authors:  Emmanuel E Comoy; Jacqueline Mikol; Jean-Philippe Deslys
Journal:  Prion       Date:  2018-08-16       Impact factor: 3.931

4.  Effects of relocation on immunological and physiological measures in female squirrel monkeys (Saimiri boliviensis boliviensis).

Authors:  Pramod N Nehete; Bharti P Nehete; Greg K Wilkerson; Steve J Schapiro; Lawrence E Williams
Journal:  PLoS One       Date:  2021-02-26       Impact factor: 3.240

Review 5.  Detection of Pathognomonic Biomarker PrPSc and the Contribution of Cell Free-Amplification Techniques to the Diagnosis of Prion Diseases.

Authors:  Hasier Eraña; Jorge M Charco; Ezequiel González-Miranda; Sandra García-Martínez; Rafael López-Moreno; Miguel A Pérez-Castro; Carlos M Díaz-Domínguez; Adrián García-Salvador; Joaquín Castilla
Journal:  Biomolecules       Date:  2020-03-19

6.  Class C CpG Oligodeoxynucleotide Immunomodulatory Response in Aged Squirrel Monkey (Saimiri Boliviensis Boliviensis).

Authors:  Pramod N Nehete; Lawrence E Williams; Sriram Chitta; Bharti P Nehete; Akash G Patel; Margish D Ramani; Thomas Wisniewski; Henrieta Scholtzova
Journal:  Front Aging Neurosci       Date:  2020-03-03       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.